Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $21.5M fell 21.6% year over year, in line with the -21.9% change in trailing-twelve-month research & development. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +29.1% a year.

Context

  • Research & development amounted to 32.1% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -21.6% holds above the trailing-twelve-month pace of -21.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$21.5M-1.7% QoQ
Last fiscal yearDec 2025
$95.14M-14.6% YoY
LTMMar 2026
$88.26M-21.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.6%——
1 year-14.6%——
3-year CAGR+29.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
95.14M USD
Year-over-year change
-14.6%
4-year CAGR
+7.8%

Research & Development vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's LTM Mar 2026 research & development of $88.26M is the 2nd highest of the 3 companies compared; the peer median is $167.02M.
  • Its year-over-year change of -21.9% is the lowest of 3, against a peer median of +40.1%.
  • Research & development amounts to 24.4% of revenue for IRWD, versus a peer median of 152.2%.
IRWD Competitors Peer median
Research & Development for IRWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$259.72M +46.3%+43.1%287.0%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$88.26M -21.9%+29.1%24.4%
ARDXArdelyx, Inc.LTM Mar 2026$74.32M +33.9%+24.8%17.4%
Peer median (excluding IRWD) $167.02M+40.1%+34.0%152.2%

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue413.75M410.6M442.74M351.41M296.15M
Cost of Revenue70.41M1.42M6.15M7.55M0
Gross Profit343.35M409.18M436.59M343.86M296.15M
Gross Margin83.0%99.7%98.6%97.9%100.0%
Research & Development70.41M44.27M116.09M111.42M95.14M
Selling, General & Admin0115.99M0082.26M
Operating Expenses111.09M158.84M1.38B250.73M177.39M
Depreciation & Amortization1.52M1.42M1.58M2.01M1.88M
EBITDA233.74M261.44M197.41M97.73M104.65M
EBITDA Margin56.5%63.7%44.6%27.8%35.3%
Operating Income232.26M250.34M(945.43M)93.12M118.76M
Operating Margin56.1%61.0%-213.5%26.5%40.1%
Interest Income726K9.5M18.97M4.47M4.08M
Interest Expense31.15M7.6M21.63M33.03M32.75M
Other Income / Expenses(31.6M)2.09M(2.64M)(27.93M)(48.73M)
Income Before Tax200.66M252.42M(948.07M)65.2M70.03M
Pre-Tax Margin48.5%61.5%-214.1%18.6%23.6%
Income Tax Expense(327.79M)77.36M83.49M64.32M46.01M
Net Income528.45M175.07M(1B)880K24.02M
Net Margin127.7%42.6%-226.4%0.3%8.1%
EPS (Basic)3.261.13(6.45)0.010.15
EPS (Diluted)3.210.96(6.45)0.010.15
Weighted Avg Shares162.25M154.37M155.44M159.08M162.22M
Weighted Avg Shares (Diluted)164.42M186.31M155.44M160.08M177.76M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.